INS and type 2 diabetes mellitus: The phase III studies LixiLan‐L and LixiLan‐O investigated the efficacy and safety of iGlarLixi versus therapy with either lixisenatide or insulin glargine; results indicate that the combination product is both effective and safe in people with T2DM.7, 8 In Japan, the product has been modified to a 1:1 combination (1 unit of insulin glargine to 1 μg lixisenatide), which better suits Japanese patients' needs.